Assessment of micro-scale anaerobic digestion for management of urban organic waste: A case study in London, UK.

This paper describes the analysis of an AD plant that is novel in that it is located in an urban environment, built on a micro-scale, fed on food and catering waste, and operates as a purposeful system. The plant was built in 2013 and continues to operate to date, processing urban food waste and generating biogas for use in a community café. The plant was monitored for a period of 319days during 2014, during which the operational parameters, biological stability and energy requirements of the plant were assessed. The plant processed 4574kg of food waste during this time, producing 1008m3 of biogas at average 60.6% methane. The results showed that the plant was capable of stable operation despite large fluctuations in the rate and type of feed. Another innovative aspect of the plant was that it was equipped with a pre-digester tank and automated feeding, which reduced the effect of feedstock variations on the digestion process. Towards the end of the testing period, a rise in the concentration of volatile fatty acids and ammonia was detected in the digestate, indicating biological instability, and this was successfully remedied by adding trace elements. The energy balance and coefficient of performance (COP) of the system were calculated, which concluded that the system used 49% less heat energy by being housed in a greenhouse, achieved a net positive energy balance and potential COP of 3.16 and 5.55 based on electrical and heat energy, respectively. Greenhouse gas emissions analysis concluded that the most important contribution of the plant to the mitigation of greenhouse gases was the avoidance of on-site fossil fuel use, followed by the diversion of food waste from landfill and that the plant could result in carbon reduction of 2.95kg CO2eq kWh-1 electricity production or 0.741kg CO2eq kg-1 waste treated.

Modelling the anaerobic digestion of solid organic waste - Substrate characterisation method for ADM1 using a combined biochemical and kinetic parameter estimation approach.

This work proposes a novel and rigorous substrate characterisation methodology to be used with ADM1 to simulate the anaerobic digestion of solid organic waste. The proposed method uses data from both direct substrate analysis and the methane production from laboratory scale anaerobic digestion experiments and involves assessment of four substrate fractionation models. The models partition the organic matter into a mixture of particulate and soluble fractions with the decision on the most suitable model being made on quality of fit between experimental and simulated data and the uncertainty of the calibrated parameters. The method was tested using samples of domestic green and food waste and using experimental data from both short batch tests and longer semi-continuous trials. The results showed that in general an increased fractionation model complexity led to better fit but with increased uncertainty. When using batch test data the most suitable model for green waste included one particulate and one soluble fraction, whereas for food waste two particulate fractions were needed. With richer semi-continuous datasets, the parameter estimation resulted in less uncertainty therefore allowing the description of the substrate with a more complex model. The resulting substrate characterisations and fractionation models obtained from batch test data, for both waste samples, were used to validate the method using semi-continuous experimental data and showed good prediction of methane production, biogas composition, total and volatile solids, ammonia and alkalinity.

Shea meal and cotton stalk as potential fuels for co-combustion with coal.

The efficient management of waste biomass is an important environmental problem in agricultural countries. Often land-fill is the main disposal route with ramifications including CH(4) release having 21 times greater global warming potential per molecule than CO(2). Biomasses are considered to be CO(2)-neutral fuels when combusted. Moreover, they are renewable and covered by the renewable obligation scheme and eligible for certificates in the UK. The overall objective of the investigation is to assess the performance of selected biomass and coal co-firing under two different modes of operation, air-staging and fuel-staging with the benefit of reduced-NO(x) and SO(2) emissions in power plant. The biomasses chosen for the study, shea meal (SM) and cotton stalk (CS) have very different cellulose/lignin compositions and different reported thermal behaviour. A series of experiments have been carried out in a 20 kW, down fired combustor using coal, shea meal-coal and cotton stalk-coal blends under un-staged, air-staged and fuel-staged co-combustion configurations. For air-staging, an optimum value of primary zone stoichiometry SR(1)=0.9 was found. Keeping it fixed, the shea meal and cotton stalk content in the coal-biomass blends was set to 5%, 10% and 15% on thermal basis. NO reductions of 51% and 60% were achieved using SM and CS, respectively, with an optimum thermal biomass blending ratio (BBR) of 10%. The results obtained were compared with un-staged and air-staged results for coal without the addition of biomass. Similarly for fuel-staging, keeping the length of the reburn and burnout zone fixed, SM and CS were evaluated as reductive fuel using different reburn fuel fractions (R(ff)) of 5%, 10%, 15% and 20%. NO reductions of 83% and 84% were obtained with an optimum R(ff) of 15% with an optimum reburn zone stoichiometry of SR(2)=0.8 for both SM and CS, respectively. SO(2) reduction and char burnout efficiency were also evaluated. It was found that addition of biomass coupled with air and fuel-staging techniques reduced-NO(x) and SO(2) simultaneously while at the same time improving the char burnout efficiency.

Effect of oxygenated liquid additives on the urea based SNCR process.

An experimental investigation was performed to study the effect of oxygenated liquid additives, H(2)O(2), C(2)H(5)OH, C(2)H(4)(OH)(2) and C(3)H(5)(OH)(3) on NO(x) removal from flue gases by the selective non-catalytic reduction (SNCR) process using urea as a reducing agent. Experiments were performed with a 150kW pilot scale reactor in which a simulated flue gas was generated by the combustion of methane operating with 6% excess oxygen in flue gases. The desired levels of initial NO(x) (500ppm) were achieved by doping the fuel gas with ammonia. Experiments were performed throughout the temperature range of interest, i.e. from 800 to 1200 degrees C for the investigation of the effects of the process additives on the performance of aqueous urea DeNO(x). With H(2)O(2) addition a downward shift of 150 degrees C in the peak reduction temperature from 1130 to 980 degrees C was observed during the experimentation, however, the peak reduction efficiency was reduced from 81 to 63% when no additive was used. The gradual addition of C(2)H(5)OH up to a molar ratio of 2.0 further impairs the peak NO(x) reduction efficiency by reducing it to 50% but this is accompanied by a downward shift of 180 degrees C in the peak reduction temperature. Further exploration using C(2)H(4)(OH)(2) suggested that a 50% reduction could be attained for all the temperatures higher than 940 degrees C. The use of C(3)H(5)(OH)(3) as a secondary additive has a significant effect on the peak reduction efficiency that decreased to 40% the reductions were achievable at a much lower temperature of 800 degrees C showing a downward shift of 330 degrees C.

Thermal analysis and devolatilization kinetics of cotton stalk, sugar cane bagasse and shea meal under nitrogen and air atmospheres.

Thermal degradation, reactivity and kinetics for biomass materials cotton stalk (CS), sugarcane bagasse 1 (SB1), sugarcane bagasse 2 (SB2) and shea meal (SM) have been evaluated under pyrolysis (N(2)) and oxidising (dry air) conditions, using a non-isothermal thermogravimetric method (TGA). In the cases of CS and SB1 the peak temperatures were 51 degrees C higher for pyrolysis compared with oxidative degradation, whereas for SB2 and SM the difference was approximately 38 degrees C. However, the differences in the rates of weight loss were significantly higher under oxidising conditions for all the materials studied. Maximum rate of weight loss (%s(-1)) under pyrolysis conditions ranged from 0.10 to 0.18 whereas these values accelerated to the range of 0.19-0.28 under oxidising conditions, corresponding to respective peak temperatures. Samples ranked in order of reactivity (R(M)x10(3)) (%s(-1) degrees C(-1)) are CS=1.31 approximately SM=1.30>SB2=1.14>SB1=0.94 for air and CS=0.54>SB2=0.49>SB1=0.45>SM=0.31 for nitrogen. Shea meal exhibited a complex char combustion behaviour indicating that there may be two distinct types of char derived from fibrous and woody components in the original material. Activation energy calculations were based on the Arrhenius correlation.

Experimental and modeling study of the effect of CO and H2 on the urea DeNO(x) process in a 150kW laboratory reactor.

An experimental and modeling investigation has been performed to study the effect of process additives, H2 and CO on NO(x) removal from flue gases by a selective non-catalytic reduction process using urea as a reducing agent. Experiments were performed with a flow reactor in which flue gas was generated by the combustion of propane in air at 3% excess oxygen and the desired levels of initial NO(x) (500ppm) were achieved by doping the flame with ammonia. Experiments were performed throughout the temperature range of interest, i.e. from 850 to 1200 degrees C for investigation of the effects of the process additives on the performance of aqueous urea DeNO(x). Subsequently, computational kinetic modeling with SENKIN code was performed to analyze the performance of urea providing a direct comparison of modeling prediction with experimental measurements. With CO addition, a downwards shift of 215 degrees C in the peak reduction temperature from 1125 to 910 degrees C was observed during the experimentation while the kinetic modeling suggests it to be 150 degrees C, i.e. from 1020 to 870 degrees C. The addition of H2 impairs the peak NO(x) reduction but suggests a low temperature application of the process. A downward shift of 250 degrees C in the peak reduction temperature, from 1020 to 770 degrees C, was observed during kinetic modeling studies. The kinetic modeling shows a good qualitative agreement with the experimental observations and reveals additional information about the process.

Investigation of SO2, HCl and NOx, control from waste incinerators using a novel additive in a pilot scale reactor.

A pilot scale experimental investigation of the use of a novel additive, calcium magnesium acetate, for the simultaneous control of SO2, HCl and NOx has been carried out. The pilot scale reactor simulated the furnace and flue gas conditions of a typical large scale waste incinerator and was a vertical 4m high reactor operated at 80 kW. The calcium magnesium acetate was added as a wet spray to the reactor at temperatures above 750 degrees C. The influence of the calcium magnesium acetate dose rate was investigated on the simultaneous removal of SO2, HCl and NOx. Maximum reductions were achieved at a Ca/S ratio (or Ca/Cl ratio) of 2.5 and were, 70% for SO2, 45% for HCl and 18% for NOx for each of the pollutant gases respectively.

Relief of sore throat with the anti-inflammatory throat lozenge flurbiprofen 8.75 mg: a randomised, double-blind, placebo-controlled study of efficacy and safety.

In this double-blind study, 301 patients with subjective and objective signs of sore throat were randomly assigned to flurbiprofen 8.75 mg (n = 129), flurbiprofen 12.5 mg (n = 43) or placebo (demulcent lozenge without active drug [n = 129]). Efficacy was assessed by changes in subjective rating scales primarily after a single dose and also over a 4-day period. Flurbiprofen 8.75 mg was superior to placebo in a number of efficacy parameters, notably throat soreness. Throat soreness was significantly reduced after 15 minutes (p < 0.05), with effects sustained for at least 2 hours (p < 0.05). Multiple dosing with flurbiprofen 8.75 mg lozenges continued to provide effective symptomatic relief over the 4-day treatment period. The small sample size was considered contributory to the variable results obtained with flurbiprofen 12.5 mg lozenges, but overall these were not inconsistent with previous trials. Both treatments were tolerated well. Flurbiprofen 8.75 mg lozenges provide an effective and well tolerated treatment for sore throat.

Repeated-dose pharmacodynamics of clopidogrel in healthy subjects.

The effect of repeated doses of clopidogrel, a novel platelet ADP-receptor antagonist, on platelet aggregation and its tolerance were assessed in two randomized, double-blind studies in healthy male adults. In each of the four successive dose groups in Study I, 6 subjects received either clopidogrel 25, 50, 100, or 150 mg once daily and 2 received placebo for 16 days, according to a rising dose design. In each of the three successive treatment groups of Study II, 9 subjects received clopidogrel (50, 75, or 100 mg once daily) in the morning, 3 received triclopidine 250 mg twice daily and 3 received placebo for 14 days. In both studies, the inhibition of platelet aggregation induced by 5 microM of ADP was measured before dosing (baseline), then at regular intervals during and after treatment. Bleeding time was generally assessed at the same time points as platelet aggregation. In both studies, the inhibition of platelet aggregation reached steady state after day 6 dosing. Mean steady-state percent inhibition of platelet aggregation was 30%, 46%, 53%, and 73% for clopidogrel 25, 50, 100, and 150 mg, respectively, in Study I; and 54%, 52%, 47%, and 43% for clopidogrel 50, 75, 100 mg, and for ticlopidine, respectively, in Study II. After treatment discontinuation, statistically significant inhibition of platelet aggregation persisted for up to 8 days. In Study I, up to 75 mg repeated doses, mean bleeding time prolongation factor did not exceed 2, but increased further to 3.5 and 5.5 at a clopidogrel dose of 100 mg and 150 mg, respectively. In study II, prolongation factors during treatment did not exceed 2.2 for clopidogrel (in the 75 mg dose group) and 1.6 for ticlopidine 500 mg. Recovery of bleeding time was observed within 7-8 days. Treatments were well tolerated, and no serious clinical events or important changes in laboratory parameters were recorded. These data were consistent with those obtained in atherosclerotic patients and showed that the plateau response for the inhibition of platelet aggregation was reached at the 75 mg dose, for which bleeding time prolongation was approximately 2.

A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers.

AIMS: The aim of this study was to compare the cardiovascular effects of levobupivacaine with those of rac-bupivacaine following i.v. administration to 14 healthy male volunteers. METHODS: Drugs were infused (at 10 mg min(-1)) using a randomized, double-blind, complete crossover procedure with a washout period of at least 1 week. The administration of drug was discontinued on the appearance of defined CNS symptoms or when a total of 150 mg had been given. Parameters measured were arterial blood pressure, heart rate, ECG, ejection fraction, acceleration index, stroke index and cardiac index. RESULTS: The mean doses administered were 56.1 mg and 47.9 mg for levobupivacaine and rac-bupivacaine respectively and the maximum mean plasma concentrations were 2.62 and 2.25 microg ml(-1) respectively. Despite the dose and plasma concentrations being comparable, levobupivacaine produced a statistically significant smaller reduction in mean stroke index (-5.14 vs -11.86 ml m(-2), P=0.001), acceleration index (-0.09 vs -0.20 s(-2), P=0.011) and the ejection fraction (-2.50 vs -4.29%, P=0.024). Both levobupivacaine (non significant) and rac-bupivacaine (significant) produced small increases in the PR interval and the corrected QT interval and although the effects of rac-bupivacaine appeared to be greater the difference between the two drugs was not significant. CONCLUSIONS: In conclusion, this study has shown that following i.v. administration levobupivacaine produces significantly less effects on cardiovascular function than does rac-bupivacaine. In particular the negative inotropic effect for levobupivacaine was less than that for rac-bupivacaine as indicated by changes in stroke index, acceleration index and ejection fraction.

The local anaesthetic activity of levobupivacaine does not differ from racemic bupivacaine (Marcain): first clinical evidence.

The local anaesthetic efficacy of levobupivacaine was compared with racemic bupivacaine (Marcain) in healthy male volunteers who were undergoing ulnar nerve blockade. Levobupivacaine, like racemic bupivacaine, produced blockade of nerve function with evidence of a dose response relationship for levobupivacaine. There were no statistically significant differences with respect to duration of sensory pain, sensory touch or motor block when the adjusted mean for the levobupivacaine groups (0.125, 0.25 and 0.5%) were compared with the 0.25% racemic bupivacaine control group. It is concluded that levobupivacaine is an effective local anaesthetic in humans with a dose-related duration of effect. Its local anaesthetic effect did not differ from that of racemic bupivacaine.

Pharmaceutical registration and how to get a drug on the market.

In this article we describe how to get a drug onto the market and outline the product development stages. Drug development programmes and regulatory control processes are complex, so only a basic outline will be given.

Novel delivery systems: electrotransport.

Electrotransport involves the transport of ionized drugs across the skin under the influence of an electric current. This method of delivery has been used for many years to deliver drugs locally to the skin or the mouth, but now it is being studied as a means of delivering drugs for their systemic effects. Opioid analgesics may be administered via this route.

Temafloxacin does not potentiate the anticoagulant effect of warfarin in healthy subjects.

The potential for drug interaction between temafloxacin, a new fluorinated quinolone antibiotic, and low-intensity warfarin was studied in 10 healthy male volunteers. Warfarin was administered orally at titrated dosages to maintain the International Normalised Ratio between 1.3 and 1.7, and was kept constant during the last 4 days of the 16-day trial, when temafloxacin 600mg twice daily was coadministered. Prothrombin times during temafloxacin and warfarin administration were similar to those during warfarin alone. Thus, temafloxacin did not potentiate the anticoagulant effect of warfarin 1.5 to 5.5mg daily in healthy volunteers.

No effect of cisapride on paracetamol absorption after oral simultaneous administration.

We have measured the effect of oral cisapride on paracetamol absorption in 12 healthy volunteers in a double-blind placebo-controlled study. Volunteers received paracetamol plus placebo, paracetamol plus cisapride 10 mg and paracetamol plus cisapride 20 mg. Mean plasma paracetamol AUC at 60 min were 1070, 1051 and 1031 micrograms.min.ml-1 and maximum paracetamol concentrations were 31.5, 29.3 and 27.4 micrograms.ml-1 respectively (no significant differences). There was no difference also in time to maximum paracetamol concentration [median (range) 30 (15-120), 30 (15-90) and 30 (15-60) min, respectively]. .

Continuous ambulatory ECG monitoring in the perioperative period: relationship of preoperative status and outcome.

We have used continuous ambulatory electrocardiography in the perioperative period to monitor 108 patients with known cardiovascular disease undergoing non-cardiac surgery. There was a high incidence of ischaemic ST segment changes and ventricular arrhythmias. For the group as a whole, anaesthesia and surgery were followed by increased ventricular ectopic activity, but did not worsen myocardial ischaemia. However, the mean duration of ischaemic ST segment changes was increased significantly in those patients with treated hypertension. Of the risk factors considered, preoperative ischaemia and peroperative systolic arterial pressure were significant correlates with postoperative myocardial ischaemia.

Temazepam absorption in patients before surgery.

We have compared the rates of absorption and efficacies of temazepam 30 mg in elixir and capsule formulations in 100 patients before surgery. Both formulations provided anxiolysis and sedation, but there was wide variation in plasma concentrations of temazepam between individuals and between formulations. The presence or absence of anxiety did not influence the absorption of the preparations. It is suggested that plasma concentrations in excess of 200 ng ml-1 are required for sedation and anxiolysis, and that this may be achieved more reliably using the elixir formulation.

Effect of different rates of infusion of propofol for induction of anaesthesia in elderly patients.

The effect of changing the rate of infusion of propofol for induction of anaesthesia was studied in 60 elderly patients. Propofol was administered at 300, 600 or 1200 ml h-1 until loss of consciousness (as judged by loss of verbal contact with the patient) had been achieved. The duration of induction was significantly longer (P less than 0.001) with the slower infusion rates (104, 68 and 51 s), but the total dose used was significantly less (P less than 0.001) in these patients (1.2, 1.6 and 2.5 mg kg-1, respectively). The decrease in systolic and diastolic arterial pressure was significantly less in the 300-ml h-1 group at the end of induction and immediately after induction (P less than 0.01). The incidence of apnoea was also significantly less in the slower infusion group.